金石亚药: 关于向全资子公司增资的公告

Group 1 - The company Sichuan Jinshi Asia Pharmaceutical Co., Ltd. plans to increase the capital of its wholly-owned subsidiary Zhejiang Yake Pharmaceutical Co., Ltd. by 200 million RMB, raising its registered capital from 150 million RMB to 350 million RMB [1] - The board of directors approved the capital increase without requiring shareholder meeting approval, as it falls within the board's authority [1] - The capital increase does not constitute a major asset restructuring as defined by relevant regulations [1] Group 2 - The financial data for Yake Pharmaceutical shows total assets of approximately 521.99 million RMB and net assets of approximately 461.59 million RMB as of December 31, 2024 [1] - The company reported a revenue of approximately 34.09 million RMB for the year 2024, with a net loss of approximately 13.69 million RMB [1] - The first quarter of 2025 shows a revenue of approximately 5.64 million RMB and a net loss of approximately 2.35 million RMB [1]